{
    "clinical_study": {
        "@rank": "158127", 
        "arm_group": [
            {
                "arm_group_label": "Cabozantinib", 
                "arm_group_type": "Experimental", 
                "description": "Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs\n      that have effects on tumour growth, blood supply, invasion and spread.\n\n      Therefore, we want to find out whether taking cabozantinib after treatment with surgery and\n      chemotherapy is effective and safe for patients who responded or had stable disease after\n      their chemotherapy.\n\n      All participants will receive 4-6 cycles of standard chemotherapy. Those with stabilization\n      or response to the standard chemotherapy will be split into 2 groups (cabozantinib or\n      placebo)."
        }, 
        "brief_title": "IRCI Gynae Sarcomas, High Grade Uterine Sarcoma", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Uterine Sarcoma", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Locally advanced: newly diagnosed HGUS with advanced disease (stage III or stage IV)\n             or residual disease after primary surgery\n\n          -  Metastatic: diagnosed with disease relapse after local treatment for primary tumor\n\n          -  at least 18 years old\n\n          -  written informed consent\n\n          -  Central pathological confirmation: Histological evidence of HGUS\n\n          -  Non-progressive patients (CR, PR, SD) at the end of the first line treatment\n             (standard chemotherapy consisting of 4 to 6 cycles of anthracyclines alone or in\n             combination with ifosfamide)\n\n          -  WHO/ECOG performance status 0-2\n\n          -  Adequate organ and bone marrow function within 3 days prior to the first dose of\n             study treatment (Cabozantinib/placebo)\n\n          -  Clinically normal cardiac function\n\n          -  Women of child bearing potential must have a negative serum/urine pregnancy test\n             within 3 days prior to the first dose of study treatment\n\n          -  adequate birth control measures\n\n        Exclusion Criteria:\n\n          -  low grade sarcoma (ESS & leiomyosarcoma), leiomyosarcoma (intermediate & high grade),\n             carcinosarcoma, adenosarcoma, rhabdomyosarcoma (alveolar or embryonal) and soft\n             tissue Primitive Neuroectodermal Tumors of uterus/cervix.\n\n          -  contraindications to cabozantinib\n\n          -  not able to swallow and retain oral tablets\n\n          -  planned use of chemotherapy, radiation therapy, radionuclide treatment, small\n             molecule tyrosine kinase inhibitor or hormonal therapy, and any other investigational\n             agent (Cabozantinib/placebo) during the treatment period\n\n          -  concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before\n             the first dose of study treatment\n\n          -  patient with poorly controlled hypertension defined at baseline as blood pressure\n             >150/90\n\n          -  patients who have suffered a cerebrovascular accident at any time in the past,\n             patients who have suffered a transient ischemic attack in the past 6 months, patients\n             who have suffered a deep venous thrombosis (DVT) or a pulmonary embolism in the past\n             6 months\n\n          -  Gastrointestinal disorders\n\n          -  patients with radiographic evidence of cavitating pulmonary lesion(s)\n\n          -  patients with tumor in contact with, invading or encasing any major blood vessels\n\n          -  patients evidence of tumor invading the GI tract\n\n          -  evidence of active bleeding or bleeding diathesis\n\n          -  hemoptysis \u2265 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose\n             of study treatment\n\n          -  signs indicative of pulmonary hemorrhage within 3 months before the first dose of\n             study treatment\n\n          -  clinically-significant gastrointestinal bleeding within 6 months before the first\n             dose of study treatment\n\n          -  prior major surgery or trauma within 6 weeks prior to first dose of study drug and\n             any wound, fracture, or ulcer should be completely healed\n\n          -  concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450\n             3A4/5"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01979393", 
            "org_study_id": "EORTC-62113-55115", 
            "secondary_id": [
                "2013\u2010000762\u201011", 
                "UC1306"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cabozantinib", 
                    "Placebo"
                ], 
                "intervention_name": "Cabozantinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Locally advanced", 
            "stage III", 
            "stage IV", 
            "residual disease after primary surgery", 
            "newly diagnosed HGUS", 
            "Metastatic"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment", 
        "overall_contact": {
            "email": "angelique.deleersnijder@eortc.be", 
            "last_name": "Ang\u00e9lique Deleersnijder", 
            "phone": "+32 2 7741035"
        }, 
        "overall_contact_backup": {
            "email": "vinciane.vinckx@eortc.be", 
            "last_name": "Vinciane Vinckx", 
            "phone": "+32 2 7741032"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
                "last_name": "Isabelle Ray-Coquard, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital , Glasgow, United Kingdom", 
                "last_name": "Nicholas Reed, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Agency for Health and Food Safety", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: Ethics Committee", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Sweden: Medical Products Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is PFS rate at 4 months after randomization to cabozantinib or placebo", 
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "3.5 years from first patient in"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01979393"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "3.5 years from first patient in"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3.5 years from first patient in"
            }, 
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "3.5 years from first patient in"
            }, 
            {
                "measure": "Duration of response to cabozantinib", 
                "safety_issue": "No", 
                "time_frame": "3.5 years from first patient in"
            }, 
            {
                "measure": "Response rate to anthracycline-based chemotherapy for the patients with measurable disease", 
                "safety_issue": "No", 
                "time_frame": "3.5 years from first patient in"
            }, 
            {
                "description": "The primary health-related quality of life endpoint that is considered of interest for this study is the global health status/QoL scale", 
                "measure": "Assessment of global health status/QoL scale", 
                "safety_issue": "No", 
                "time_frame": "3.5 years from first patient in"
            }, 
            {
                "description": "This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.", 
                "measure": "Occurence of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "3.5 years from first patient in"
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Gynecologic Oncology Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "NHS Greater Glasgow and Clyde", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}